keyword
MENU ▼
Read by QxMD icon Read
search

Ovarian carcinomatosis

keyword
https://www.readbyqxmd.com/read/28315929/adnexal-masses-associated-with-peritoneal-involvement-diagnosis-with-ct-and-mri
#1
REVIEW
Audrey Ognong-Boulemo, Anthony Dohan, Christine Hoeffel, Agatha Stanek, François Golfier, Olivier Glehen, Pierre-Jean Valette, Pascal Rousset
Given the unique intra-peritoneal anatomic location of the adnexa, tubo-ovarian diseases can commonly spread into the peritoneal cavity. Peritoneal seeding may occur in a spectrum of adnexal conditions including infectious diseases, endometriosis, and benign or malignant primary or secondary ovarian tumors. CT is usually the imaging modality on which the concomitant involvement of the peritoneum and the ovary is depicted. The first diagnosis to be considered by the radiologist is generally peritoneal carcinomatosis from ovarian cancer but other conditions cited above have also to be borne in mind and may be suggested on the basis of careful assessment of CT findings or on further MR findings...
March 18, 2017: Abdominal Radiology
https://www.readbyqxmd.com/read/28254228/difficulty-in-diagnosis-and-different-prognoses-between-colorectal-cancer-with-ovarian-metastasis-and-advanced-ovarian-cancer-an-empirical-study-of-different-surgical-adoptions
#2
Ko-Chao Lee, Hao Lin, Chan-Chao ChangChien, Hung-Chun Fu, Ching-Chou Tsai, Chen-Hsuan Wu, Yu-Che Ou
OBJECTIVE: To determine the clinical manifestations and optimal management of female patients with advanced colorectal cancer (CRC) metastasis in ovaries mimicking advanced ovarian malignancy. MATERIALS AND METHODS: A retrospective medical records review of female patients with primary CRC metastasis to ovaries, which were initially diagnosed as ovarian malignancy, and treated between 2001 and 2013. Clinical presentations, pathologic findings, and treatment outcomes were analyzed...
February 2017: Taiwanese Journal of Obstetrics & Gynecology
https://www.readbyqxmd.com/read/28247413/mesothelial-to-mesenchymal-transition-as-a-possible-therapeutic-target-in-peritoneal-metastasis-of-ovarian-cancer
#3
Angela Rynne-Vidal, Chi Lam Au-Yeung, José A Jiménez-Heffernan, María Luisa Pérez-Lozano, Lucía Cremades-Jimeno, Carmen Bárcena, Ignacio Cristóbal-García, Concepción Fernández-Chacón, Tsz Lun Yeung, Samuel C Mok, Pilar Sandoval, Manuel López-Cabrera
Peritoneal dissemination is the primary metastatic route of ovarian cancer (OvCa), often accompanied by accumulation of ascitic fluid. The peritoneal cavity is lined by mesothelial cells (MCs), which can convert into carcinoma-associated fibroblasts (CAFs) through mesothelial-to-mesenchymal transition (MMT). Here, we demonstrate that MCs isolated from ascitic fluid (AFMCs) of OvCa patients with peritoneal implants also undergo MMT and promote subcutaneous tumour growth in mice. RNA sequencing of AFMCs revealed that MMT-related pathways-including TGF-β signalling-are differentially regulated, and a gene signature was verified in peritoneal implants from OvCa patients...
March 1, 2017: Journal of Pathology
https://www.readbyqxmd.com/read/28210074/second-look-surgery-plus-hyperthermic-intraperitoneal-chemotherapy-for-patients-with-colorectal-cancer-at-high-risk-of-peritoneal-carcinomatosis-does-it-really-save-lives
#4
EDITORIAL
Delia Cortes-Guiral, Dominique Elias, Pedro Antonio Cascales-Campos, Alfredo Badía Yébenes, Ismael Guijo Castellano, Ana Isabel León Carbonero, José Ignacio Martín Valadés, Jesus Garcia-Foncillas, Damian Garcia-Olmo
The treatment of peritoneal carcinomatosis (PC) of colorectal origin with cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) has a 5-year recurrence-free or cure rate of at least 16%, so it is no longer labeled as a fatal disease, and offers prolonged survival for patients with a low peritoneal carcinomatosis index. Metachronous PC of colorectal origin is so predictable that there is a model which has been used to successfully determine the individual risk of each patient. Patients at risk are clearly identified; those with the highest risk have small peritoneal nodules present in the first surgery (70% probability of developing PC), ovarian metastases (60%), perforated tumor onset or intraoperative tumor rupture (50%)...
January 21, 2017: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/28133300/-a-case-of-undifferentiated-carcinoma-of-the-sigmoid-colon-that-responded-to-paclitaxel-and-carboplatin-chemotherapy
#5
Shingo Toyama, Katsuyoshi Kudoh, Shinobu Ohnuma, Satoko Sato, Naoki Tanaka, Takeshi Aoki, Hirofumi Imoto, Hideaki Karasawa, Kazuhiro Watanabe, Munenori Nagao, Tomoya Abe, Hiroaki Musha, Fuyuhiko Motoi, Takeshi Naitoh, Michiaki Unno
We report a case of a 72-year-old woman who was initially diagnosed with ovarian cancer with peritoneal carcinomatosis. Systemic chemotherapy consisting of paclitaxel and carboplatin(TC)was administered. Although a partial response(PR)was achieved after the 4 courses of TC, this regimen was discontinued due to severe adverse events. Ten months after discontinuation of TC, because abdominal CT and colonoscopy showed an intra-tumoral abscess caused by invasion of the tumor to the sigmoid colon, abdominal total hysterectomy, bilateral salpingo-oophorectomy, and a Hartmann's operation were performed to control the disease symptoms...
November 2016: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/28118296/malignancy-risk-of-sonographically-benign-appearing-purely-solid-adnexal-masses-in-asymptomatic-postmenopausal-women
#6
Juan Luis Alcazar, Maria Angela Pascual, Reyes Marquez, Silvia Ajossa, Leire Juez, Betlem Graupera, Alba Piras, Lourdes Hereter, Stefano Guerriero
OBJECTIVE: To assess the natural history of benign appearing purely solid ovarian lesions in asymptomatic postmenopausal women. METHODS: Retrospective observational cohort study comprising 99 women (mean age, 58.2 years, ranging from 50 to 77 years) diagnosed as having a purely solid ovarian lesion at transvaginal ultrasound between April 2001 and October 2015. Inclusion criteria were as follows: asymptomatic postmenopausal women with a well-defined purely solid ovarian lesion with International Ovarian Tumor Analysis color score 1 or 2, without ascites and/or signs of carcinomatosis...
January 23, 2017: Menopause: the Journal of the North American Menopause Society
https://www.readbyqxmd.com/read/28109627/a-final-report-of-a-phase-i-study-of-veliparib-abt-888-in-combination-with-low-dose-fractionated-whole-abdominal-radiation-therapy-ldfwar-in-patients-with-advanced-solid-malignancies-and-peritoneal-carcinomatosis-with-a-dose-escalation-in-ovarian-and-fallopian
#7
Kim A Reiss, Joseph M Herman, Deborah Armstrong, Marianna Zahurak, Anthony Fyles, Anthony Brade, Michael Milosevic, Laura A Dawson, Angela Scardina, Patricia Fischer, Amy Hacker-Prietz, Robert J Kinders, Lihua Wang, Alice Chen, Sarah Temkin, Naomi Horiba, Lee-Anne Stayner, Lillian L Siu, Nilofer S Azad
BACKGROUND: The combination of low-dose radiation therapy with PARP inhibition enhances anti-tumor efficacy through potentiating DNA damage. We combined low-dose fractionated whole abdominal radiation (LDFWAR) with ABT-888 in patients with peritoneal carcinomatosis with a dose escalation in ovarian and fallopian cancer patients (OV). METHODS: Patients were treated with veliparib, 40-400mg orally BID on days 1-21 of 3 28-day cycles on 6 dose levels. Dose levels 5 and 6 included only OV patients...
March 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28099801/highly-specific-and-sensitive-fluorescent-nanoprobes-for-image-guided-resection-of-sub-millimeter-peritoneal-tumors
#8
Aaron H Colby, Samantha M Berry, Ann M Moran, Kristine Amber Pasion, Rong Liu, Yolonda L Colson, Nelson Ruiz-Opazo, Mark W Grinstaff, Victoria L M Herrera
A current challenge in the treatment of peritoneal carcinomatosis is the inability to detect, visualize, and resect small or microscopic tumors of pancreatic, ovarian, or mesothelial origin. In these diseases, the completeness of primary tumor resection is directly correlated with patient survival, and hence, identifying small sub-millimeter tumors (i.e., disseminated disease) is critical. Thus, new imaging techniques and probes are needed to improve cytoreductive surgery and patient outcomes. Highly fluorescent rhodamine-labeled expansile nanoparticles (HFR-eNPs) are described for use as a visual aid during cytoreductive surgery of pancreatic carcinomatosis...
February 28, 2017: ACS Nano
https://www.readbyqxmd.com/read/28089175/reduction-of-carcinomatosis-risk-using-icodextrin-as-a-carrier-solution-of-intraperitoneal-oxaliplatin-chemotherapy
#9
I Jouvin, H Najah, C Pimpie, C Canet Jourdan, R Kaci, M Mirshahi, C Eveno, M Pocard
There is no standard treatment in patients with high risk metachronous peritoneal carcinomatosis (PC) in colonic cancer, as perforated tumour or synchronous ovarian metastasis. Icodextrin 4% (ICDX), presently used to prevent postoperative abdominal adhesions, could inhibit the coactivation of the tumour cells and the microenvironment cells, associated with the development of PC. The aim of this study was to inhibit the formation of the PC in a murine model mimicking surgical situation using ICDX and intraperitoneal (IP) prophylactic chemotherapy...
January 9, 2017: European Journal of Surgical Oncology
https://www.readbyqxmd.com/read/28088790/intraperitoneal-immunotherapy-with-t-cells-stably-and-transiently-expressing-anti-epcam-car-in-xenograft-models-of-peritoneal-carcinomatosis
#10
Wei Xia Ang, Zhendong Li, Zhixia Chi, Shou-Hui Du, Can Chen, Johan C K Tay, Han Chong Toh, John E Connolly, Xue Hu Xu, Shu Wang
The epithelial cell adhesion molecule (EpCAM) is overexpressed in a wide variety of tumor types, including peritoneal carcinomatosis (PC) from gastrointestinal and gynecological malignancies. To develop a chimeric antigen receptor T (CART) cell therapy approach to treat patients with end-stage PC, we constructed third generation CARs specific to EpCAM using the 4D5MOC-B single chain variable fragment. CART cells were generated with lentiviral transduction and exhibited specific in vitro killing activity against EpCAM-positive human ovarian and colorectal cancer cells...
January 10, 2017: Oncotarget
https://www.readbyqxmd.com/read/28072694/effect-of-hyperthermic-intrathoracic-chemotherapy-hithoc-on-the-malignant-pleural-effusion-a-systematic-review-and-meta-analysis
#11
REVIEW
Hua Zhou, Wei Wu, Xiaoping Tang, Jianying Zhou, Yihong Shen
BACKGROUND: Although hyperthermic intraperitoneal chemotherapy (HIPEC) has been widely used to treat malignant ascites or as a preventive strategy for microscopic carcinomatosis following surgical resection of abdominal tumors, application of hyperthermic intrathoracic chemotherapy (HITHOC) in the treatment of malignant pleural effusion is limited. The objective of the current study was to conduct a systematic review and meta-analysis on the application of HITHOC in the palliative treatment of malignant pleural effusion...
January 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28061769/intraperitoneal-cisplatin-and-doxorubicin-as-maintenance-chemotherapy-for-unresectable-ovarian-cancer-a-case-report
#12
Clemens B Tempfer, Franziska Hartmann, Ziad Hilal, Günther A Rezniczek
BACKGROUND: Primary advanced, unresectable ovarian cancer (OC) is treated with palliative systemic chemotherapy. Intraperitoneal chemotherapy may be an alternative local maintenance therapy. CASE PRESENTATION: A 75 year old woman with laparoscopically and histologically confirmed unresectable OC was treated with 13 cycles of intraperitoneal cisplatin 7.5 mg/m(2) and doxorubicin 1.5 mg/m(2) over 2 years using laparoscopic pressurized intraperitoneal aerosol chemotherapy (PIPAC)...
January 6, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28008196/clinical-characteristics-of-primary-peritoneal-carcinoma-patients-a-single-institution-experience-involving-8-patients
#13
Satomi Hattori, Hiroaki Kajiyama, Utako Fuji, Yuko Furui, Yuki Ishibashi, Yuka Hattori, Noriko Takahashi, Fumitaka Kikkawa, Toshiya Misawa
Primary peritoneal carcinoma (PPC) is treated similarly to advanced epithelial ovarian carcinoma (aEOC); however, the standard approach for the management of PPC is controversial. The objective of this study was to evaluate the clinical features and prognosis of those patients. A retrospective analysis was performed of eight patients with PPC between January 2008 and December 2015. Clinicopathologic parameters, the diagnostic modality, treatment, and oncologic outcome were analyzed. The median age at the time of diagnosis was 72...
December 2016: Nagoya Journal of Medical Science
https://www.readbyqxmd.com/read/27984747/imaging-diagnostics-in-ovarian-cancer-magnetic-resonance-imaging-and-a-scoring-system-guiding-choice-of-primary-treatment
#14
Sigrid M Kasper, Margit Dueholm, Edvard Marinovskij, Jan Blaakær
OBJECTIVE: To analyze the ability of magnetic resonance imaging (MRI) and systematic evaluation at surgery to predict optimal cytoreduction in primary advanced ovarian cancer and to develop a preoperative scoring system for cancer staging. STUDY DESIGN: Preoperative MRI and standard laparotomy were performed in 99 women with either ovarian or primary peritoneal cancer. Using univariate and multivariate logistic regression analysis of a systematic description of the tumor in nine abdominal compartments obtained by MRI and during surgery plus clinical parameters, a scoring system was designed that predicted non-optimal cytoreduction...
October 29, 2016: European Journal of Obstetrics, Gynecology, and Reproductive Biology
https://www.readbyqxmd.com/read/27906723/safety-and-outcome-measures-of-first-in-human-intraperitoneal-%C3%AE-radioimmunotherapy-with-212pb-tcmc-trastuzumab
#15
Ruby F Meredith, Julien J Torgue, Tania A Rozgaja, Eileen P Banaga, Patty W Bunch, Ronald D Alvarez, J Michael Straughn, Michael C Dobelbower, Andrew M Lowy
PURPOSE: One-year monitoring of patients receiving intraperitoneal (IP) Pb-TCMC-trastuzumab to provide long-term safety and outcome data. A secondary objective was to study 7 tumor markers for correlation with outcome. METHODS: Eighteen patients with relapsed intra-abdominal human epidermal growth factor receptor-2 expressing peritoneal metastases were treated with a single IP infusion of Pb-TCMC-trastuzumab, delivered <4 h after 4 mg/kg IV trastuzumab. Seven tumor markers were studied for correlation with outcome...
November 30, 2016: American Journal of Clinical Oncology
https://www.readbyqxmd.com/read/27900846/plasmablastic-lymphoma-mimicking-carcinomatosis-a-case-report-and-review-of-the-literature
#16
REVIEW
Andrea M Olofson, Eric Y Loo, Paul A Hill, Xiaoying Liu
First identified as a distinct disease entity in HIV-positive patients, plasmablastic lymphoma is a rare aggressive disease which arises predominantly in men and is associated with immunodeficiency of all causes. Although its exact etiology is poorly understood, Epstein-Barr virus infection and MYC gene aberrations have been implicated in its development in both HIV-positive and HIV-negative patients. The disease typically involves extranodal sites with a predilection for the oral cavity but may occur in other locations...
March 2017: Diagnostic Cytopathology
https://www.readbyqxmd.com/read/27874958/diagnostic-accuracy-of-mdct-in-the-evaluation-of-patients-with-peritoneal-carcinomatosis-from-ovarian-cancer-is-delayed-enhanced-phase-really-effective
#17
E Rodolfino, E Devicienti, M Miccò, A Del Ciello, S E Di Giovanni, M Giuliani, C Conte, B Gui, A L Valentini, L Bonomo
OBJECTIVE: To assess the diagnostic accuracy of delayed enhanced phase in addition to portal enhanced phase in MDCT imaging for depicting peritoneal carcinomatosis (PC) implants in patients with ovarian cancer. PATIENTS AND METHODS: We retrospectively reviewed double-phase, portal enhanced phase (PEP) and delayed enhanced phase (DEP), MDCT-examinations of 40 patients with clinical suspicion of recurrent PC from histopathologically-proven ovarian cancer, previously treated with both cytoreductive surgery and adjuvant/neoadjuvant chemotherapy...
November 2016: European Review for Medical and Pharmacological Sciences
https://www.readbyqxmd.com/read/27855557/201-consecutive-cytoreductive-surgery-crs-and-hyperthermic-intraperitoneal-chemotherapy-hipec-procedures-in-a-single-asian-tertiary-centre
#18
Grace Tan, Claramae Chia, Mrinal Kumar, Su Pin Choo, John Chia, Chee Kian Tham, Clarinda Chua, Khee Chee Soo, Melissa Teo
INTRODUCTION: Peritoneal carcinomatosis (PC) is increasingly being treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). We provide a review of a high-volume Asian institute's experience and survival outcomes with this procedure. METHODS: Data were prospectively collected from 201 consecutive CRS and HIPEC procedures performed in a single institution between April 2001 and November 2015. Our primary endpoints were overall survival (OS) and disease-free survival (DFS), and secondary endpoints were morbidity and mortality...
December 14, 2016: International Journal of Hyperthermia
https://www.readbyqxmd.com/read/27807188/autophagy-induction-results-in-enhanced-anoikis-resistance-in-models-of-peritoneal-disease
#19
James L Chen, Jason David, Douglas Cook-Spaeth, Sydney Casey, David Cohen, Karuppaiyah Selvendiran, Tanios Bekaii-Saab, John L Hays
Peritoneal carcinomatosis and peritoneal sarcomatosis is a potential complication of nearly all solid tumors and results in profoundly increased morbidity and mortality. Despite the ubiquity of peritoneal carcinomatosis/peritoneal sarcomatosis, there are no clinically relevant targeted therapies for either its treatment or prevention. To identify potential therapies, we developed in vitro models of peritoneal carcinomatosis/peritoneal sarcomatosis using tumor cell lines and patient-derived spheroids (PDS) that recapitulate anoikis resistance and spheroid proliferation across multiple cancer types...
January 2017: Molecular Cancer Research: MCR
https://www.readbyqxmd.com/read/27751625/paraneoplastic-systemic-sclerosis-about-3-cases-and-review-of-literature
#20
J-B Monfort, I Lazareth, P Priollet
OBJECTIVE: Association between cancer and systemic sclerosis (SSc) has been described. However, paraneoplastic SSc is not well known. The aim of this article is to describe cases of paraneoplastic systemic sclerosis and to compare them to other cases of the literature, to find characteristics that can make suspect a paraneoplastic mechanism when SSc is diagnosed. METHODS: We retrospectively analyzed patients, in our department who, over the last 15 years, presented with Raynaud's phenomenon with a diagnosis of SSc (including cancer during the period of SSc)...
December 2016: Journal des Maladies Vasculaires
keyword
keyword
64064
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"